April Cashin-Garbutt

Natural Sciences

April graduated with a first-class honours degree in Natural Sciences from Pembroke College, University of Cambridge. During her time as Editor-in-Chief, News-Medical (2012-2017), she kickstarted the content production process and helped to grow the website readership to over 60 million visitors per year.

Through interviewing global thought leaders in medicine and life sciences, including Nobel laureates, April developed a passion for neuroscience and now works at the Sainsbury Wellcome Centre for Neural Circuits and Behaviour, located within UCL.

See less

Articles from April

The future of high throughput screening: an interview with Mark Wigglesworth, Director High Throughput Screening, AstraZeneca

Quoting Mike Snowden (VP & Head of Discovery Sciences, AstraZeneca), “it’s where biology meets chemistry”. It’s where for the first time a target protein can be probed for novel molecules that modulate its function, of course we want to do this to prove a hypothesis that these proteins are drug targets with the potential to deliver innovative medicines.

20 May 2014

DNA-directed RNA interference and hepatitis C: an interview with Carl Stubbings, Chief Business Officer, Benitec Biopharma

RNA interference (RNAi) is a naturally occurring process, which cells can use to silence, or ‘turn off’ unwanted genes.

19 May 2014

Autoimmune epilepsy diagnostics: an interview with Dr. Joseph J. Higgins, Medical Director, Neurology, Athena Diagnostics, a business of Quest Diagnostics

Epilepsy is a group of neurological disorders often characterized by seizures and cognitive impairment due to electrical disturbances in the brain.

14 May 2014

SGK1 enzyme, asthma and cancer therapies: an interview with Dr. Jonathan D. Powell, Johns Hopkins Kimmel Cancer Center

SGK1 stands for serum/glucocorticoid-regulated kinase 1. SGK1 is a member of the AGC kinase family, which is a huge family of kinases.

13 May 2014

Molecular imaging and multimodality: an interview with Professor Silvio Aime, University of Turin

Molecular imaging aims at the visualization of molecules or molecular events that occur at the cellular level. Clearly it also allows the possibility of looking inside the biochemical pathway at the cellular level and therefore enables us to look at the onset of diseases well before they are resolved into structural change.

12 May 2014

Controlling low-density lipoprotein-cholesterol levels: an interview with Jay Edelberg, M.D., Sanofi and Bill Sasiela, Ph.D., Regeneron

Lipids, primarily cholesterol and triglycerides, come from two sources: what is naturally manufactured in the liver and what comes from the intestines through the diet.

7 May 2014

Mortality after cardiac surgery: an interview with Dr. Bryan G. Maxwell, Johns Hopkins Medicine

The last decade has seen a strong movement towards the use of various quality measurements to grade medical care. In surgery, 30-day mortality is one of the most common benchmarks. We wanted to determine if patterns of postoperative mortality showed any signs that the process of measuring medical care might actually alter how (and when) care is provided or withdrawn.

6 May 2014

Trends, opportunities and threats in the life science industry: an interview with Bob Coughlin, CEO, MassBio

We were extremely excited to launch the Impact 2020 report at our annual meeting. Our five-year strategic plan is focused on value, early-stage financing and ensuring more patient-centered discussions.

5 May 2014

Restoring vision in patients with retinitis pigmentosa: an interview with Dr. Gregoire Cosendai, Vice President, Europe, Second Sight

Retinitis pigmentosa (RP) is a progressive eye disease that leads to untreatable blindness. The name of the disease derives from the fact that one of the areas affected by the disease is the retinal pigment epithelium (RPE) in the back of the eye.

30 Apr 2014

The rising incidence of multi-drug resistant TB: an interview with Dr Myriam Haxaire-Theeuwes, Compound Development Team Leader, Janssen

MDR-TB is on the rise in a number of regions in the world, because progress towards targets for diagnosis and treatment of multidrug-resistant TB (MDR-TB) is far off-track.

29 Apr 2014

April Cashin-Garbutt

Articles from April

The future of high throughput screening: an interview with Mark Wigglesworth, Director High Throughput Screening, AstraZeneca

DNA-directed RNA interference and hepatitis C: an interview with Carl Stubbings, Chief Business Officer, Benitec Biopharma

Autoimmune epilepsy diagnostics: an interview with Dr. Joseph J. Higgins, Medical Director, Neurology, Athena Diagnostics, a business of Quest Diagnostics

SGK1 enzyme, asthma and cancer therapies: an interview with Dr. Jonathan D. Powell, Johns Hopkins Kimmel Cancer Center

Molecular imaging and multimodality: an interview with Professor Silvio Aime, University of Turin

Controlling low-density lipoprotein-cholesterol levels: an interview with Jay Edelberg, M.D., Sanofi and Bill Sasiela, Ph.D., Regeneron

Mortality after cardiac surgery: an interview with Dr. Bryan G. Maxwell, Johns Hopkins Medicine

Trends, opportunities and threats in the life science industry: an interview with Bob Coughlin, CEO, MassBio

Restoring vision in patients with retinitis pigmentosa: an interview with Dr. Gregoire Cosendai, Vice President, Europe, Second Sight

The rising incidence of multi-drug resistant TB: an interview with Dr Myriam Haxaire-Theeuwes, Compound Development Team Leader, Janssen

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Latest News